257
Views
17
CrossRef citations to date
0
Altmetric
Research Article

Stability study of sodium colistimethate-loaded lipid nanoparticles

, , , , , & show all
Pages 636-645 | Received 22 Feb 2016, Accepted 27 Sep 2016, Published online: 14 Oct 2016
 

Abstract

In the last decades, the encapsulation of antibiotics into nanoparticulate carriers has gained increasing attention for the treatment of infectious diseases. Sodium colistimethate-loaded solid lipid nanoparticles (Colist-SLNs) and nanostructured lipid carriers (Colist-NLCs) were designed aiming to treat the pulmonary infection associated to cystic fibrosis patients. The nanoparticles were freeze-dried using trehalose as cryoprotectant. The stability of both nanoparticles was analysed over one year according to the International Conference of Harmonisation (ICH) guidelines by determining the minimum inhibitory concentration (MIC) against clinically isolated Pseudomonas aeruginosa strains and by studying their physico-chemical characteristics. The results showed that Colist-SLNs lost their antimicrobial activity at the third month; on the contrary, the antibacterial activity of Colist-NLCs was maintained throughout the study within an adequate range (MIC ≤16 μg/mL). In addition, Colist-NLCs exhibited suitable physico-chemical properties at 5 °C and 25 °C/60% relative humidity over one year. Altogether, Colist-NLCs proved to have better stability than Colist-SLNs.

Acknowledgements

Technical and human support provided by SGIker (UPV/EHU, MICINN, GV/EJ, ERDF and ESF) is gratefully acknowledged. The authors acknowledge the support of the University of the Basque Country UPV/EHU (UFI11/32) and University of Barcelona (UB). Authors also wish to thank the intellectual and technical assistance from the Platform for Drug Formulation (NANBIOSIS) CIBER-BBN.

Disclosure statement

The authors report no declarations of interest.

Funding

This work was carried out by TERFIQEC Project, Comprehensive Research On Effective Therapies For The Treatment of Cystic Fibrosis And Associated Diseases; IPT-2011–1402-900000 funded by the Ministry of Economy and Competitiveness. M. Moreno-Sastre gratefully acknowledges the UPV/EHU for the fellowship grant.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.